Ixabepilone for locally advanced or metastatic breast cancer
 
Status Suspended
Process STA
Referral date 01 December 2007
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: 02 October 2008
1st appraisal committee meeting: TBC

Project Team

Communications manager: Sarita Tamber
Executive Lead: Gillian Leng
Project manager: Laura Malone
Technical Lead: Helen Tucker

Consultees

Manufacturers / Sponsors Bristol-Myers Squibb (ixabepilone)
Others Heart of Birmingham Teaching PCT
  Department of Health
  Telfordand Wrekin PCT
  Welsh Assembly Government
Patient / Carer Groups Afiya Trust
  Age Concern England
  Black Health Agency
  Breakthrough Breast Cancer
  Breast Cancer Campaign
  Breast Cancer Care
  Breast Cancer UK
  Breast Cancer Haven
  British Ethnic Health Awareness Foundation (BEHAF)
  CANCERactive
  Cancerbackup
  Cancer Black Care
  Cancer Equality
  Cancer Voices
  Chinese National Healthy Living Centre
  Confederation of Indian Organisations
  Counsel and Care
  Equalities National Council
  Helen Rollason Heal Cancer Charity
  Help the Aged
  IBC UK
  Macmillan Cancer Support
  Maggie's Centres
  Marie Curie Cancer Care
  Muslim Council of Great Britain
  Muslim Health Network
  National Cancer Alliance
  National Council for Palliative Care
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder Care
  Tenovus Cancer Information Centre
  Women's Health Concern
Professional groups Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association for Services to the Elderly
  British Association of Surgical Oncology
  British Geriatrics Society
  British Oncological Association
  British Psychosocial Oncology Society (BPOS)
  Cancer Networks Pharmacists Forum
  Cancer Research UK
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians' Medical Oncology Joint Special Committee
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine - Forum on Intellectual Disabilities
  United Kingdom Clinical Pharmacy Association
  United KingdomOncology Nursing Society

Commentators

Associated Guideline Groups National Collaborating Centre for Cancer
Associated Public Health Groups None
Comparator manufacturer(s) Eli Lilly & Co Ltd (gemcitabine)
  Mayne Pharma plc (paclitaxel, vinorelbine)
  Medac (UK) (vinorelbine)
  Pierre Fabre (vinorelbine)
  Roche Products Ltd (capecitabine)
  Sanofi-Aventis Ltd (docetaxel)
  Teva UK (paclitaxel)
  Wockhardt UK Ltd (paclitaxel, vinorelbine)
Evidence Review Group Evidence Review Group tbc
  National Coordinating Centre for Health Technology Assessment
General Age Concern Cymru
  Board of Community Health Councils in Wales
  British National Formulary
  Cancer Care Cymru
  Department of Health,Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Public Health Service for Wales
  NHS Alliance
  NHS Confederation
  NHS Purchasing and Supply Agency
  NHS Quality Improvement Scotland
  Scottish Medicines Consortium
Relevant research groups Against Breast Cancer Research Group
  Breast Cancer Hope
  Breast Cancer Research Trust
  Cochrane Collaboration – Cochrane Breast Cancer Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  Policy Research Institute on Ageing and Ethnicity
  Research Institute for the Care of the Elderly

Timeline

Key events during the development of the guidance:

Date Update
9 December 2008 The manufacturer recently received a negative CHMP opinion for Ixabepilone for locally advanced or metastatic breast cancer. Consequently this appraisal will be suspended until we receive an update from the manufacturer on the status of regulatory approval.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance